#074: S1P Modulators - Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory), Siponimod (Mayzent) for active RRMS & SPMS

MS-Perspektive - The Multiple Sclerosis Podcast

Learn more about the S1P Modulators, known by the brand names Gilenya, Zeposia, Ponvory, Mayzent and their usage against active RRMS & SPMS.

You can find the complete text to read on my blog: https://ms-perspektive.com/074-s1p-modulators

Today it’s all about the group of S1P modulators, which includes fingolimod (Gilenya), ozanimod (Zeposia), ponesimod (Ponvory) and siponimod (Mayzent). The first three, i.e. Gilenya, Zeposia and Ponvory, are used as a disease-modifying therapy for active multiple sclerosis. Fingolimod (Gilenya) is even approved for pediatric MS. Mayzent is approved for active SPMS if the patient is already experiencing a worsening of MS independent of relapses, but also has localized inflammatory activity.

S1P modulators are pronounced sphingosine 1-phosphate receptor modulators and prevent the leakage of lymphocytes from the lymph nodes. This also prevents them from entering the central nervous system (CNS). The S1P receptor subgroups determine the side effect profile.

Please remember that I can only provide an overview here. Your neurologist and your MS nurse should advise you in detail on the right therapy for you. This is because they know your general state of health and you should also talk about your goals, wishes, fears and preferences so that these can be taken into account.

Table of Contents

• General Information
• How are S1P Modulators – Fingolimod (Gilenya), Ozanimod (Zeposia), Ponesimod (Ponvory), Siponimod (Mayzent) classified in immunotherapies?
• What are fingolimod (Gilenya), ozanimod (Zeposia), ponesimod (Ponvory), and siponimod (Mayzent) approved for?
• What is the situation for special patient groups?
• Who should avoid fingolimod (Gilenya), ozanimod (Zeposia), ponesimod (Ponvory), and siponimod (Mayzent)?
• How do fingolimod (Gilenya), ozanimod (Zeposia), ponesimod (Ponvory), and siponimod (Mayzent) work?
• How is it taken?
• How effective are fingolimod (Gilenya), ozanimod (Zeposia), ponesimod (Ponvory), and siponimod (Mayzent)?
• Risks and side effects of fingolimod (Gilenya), ozanimod (Zeposia), ponesimod (Ponvory), and siponimod (Mayzent)
• Vaccinations
• Sources
• Final note

Sources

I used the following sources to create the content:

• Lecture on S1P receptor modulator by Prof. Dr. Tobias Derfuss as part of the Multiple Sclerosis Management Master’s program
• Quality manual of the German KKNMS on fingolimod (Gilenya),ozanimod (Zeposia),ponesimod (Ponvory),and siponimod (Mayzent)
• MS-Selfie Infocards by Prof. Dr. Gavin Giovannoni
• German Multiple Sclerosis and Fertility Registry (DMSKW)
• Information from the German interview with Prof. Dr. Barbara Kornek on pediatric MS
• German DECIMS information on fingolimod

Final note

Please remember, there is no one great medication that helps everyone, but it must always be weighed up what suits a particular person best. Other illnesses, personal goals and preferences must also be taken into account. Your neurologist and MS nurse are the right persons to talk to and can make individual recommendations. This article is for information purposes only and does not constitute a recommendation. What helps one person may not help another.

I hope that, together with your neurologist and MS nurse, you will quickly find the right immunotherapy for you. And that you can lead a fulfilled, happy and self-determined life with MS, supported by a healthy lifestyle and a dose of fortune.

---

You may also want to look at the posts on the other DMTs:

• #061: Dimethyl fumarate (Tecfidera) and diroximel fumarate (Vumerity)
• #065: Glatiramer acetate (Copaxone, Brabio)
• #068: Interferon-beta (Avonex, Betaferon, Extavia, Plegridy, Rebif)
• #070: Teriflunomide (Aubagio)
• #072: Natalizumab (Tysabri, Tyruko) for active relapsing remitting MS

See you soon and try to make the best out of your life, Nele

For more information and positive thoughts, subscribe to my newsletter for free.

Click here for an overview of all podcast episodes published so far.